The estimated Net Worth of Joseph C Scodari is at least $162 mil dollars as of 6 March 2020. Mr. Scodari owns over 8,700 units of OptiNose Inc stock worth over $19,532 and over the last 19 years he sold OPTN stock worth over $0. In addition, he makes $142,753 as Independent Chairman of the Board at OptiNose Inc.
Joseph has made over 3 trades of the OptiNose Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 8,700 units of OPTN stock worth $49,590 on 6 March 2020.
The largest trade he's ever made was buying 8,700 units of OptiNose Inc stock on 6 March 2020 worth over $49,590. On average, Joseph trades about 1,249 units every 26 days since 2006. As of 6 March 2020 he still owns at least 21,230 units of OptiNose Inc stock.
You can see the complete history of Mr. Scodari stock trades at the bottom of the page.
Joseph C. Scodari serves as Independent Chairman of the Board of the Company. Mr. Scodari has served as Chairman of our Board of Directors since October 2017. Mr. Scodari was Worldwide Chairman, Pharmaceuticals Group, of Johnson & Johnson, and a member of Johnson & Johnson's Executive Committee from March 2005 until his retirement in March 2008. From 2003 to March 2005, Mr. Scodari was Company Group Chairman of Johnson & Johnson's Biopharmaceutical Business. Mr. Scodari joined Johnson & Johnson in 1999 as President and Chief Operating Officer of Centocor Inc., when Johnson & Johnson acquired that company. Mr. Scodari joined Centocor in 1996 as President, Pharmaceutical Division and was named President and COO in 1998. Mr. Scodari began his career in 1974 in sales for Winthrop Laboratories, Division of Sterling Drug. He progressed through various management positions, eventually leading the Diagnostic Imaging Division for Winthrop and later Strategic Marketing at the Corporate level for the Imaging business. Mr. Scodari joined Rorer Pharmaceuticals (shortly thereafter, Rhône-Poulenc Rorer) in 1989 as Vice President of Marketing and Business Development. He later served as Vice President and General Manager for the United States, and subsequently, North America, and finally as Senior Vice President and General Manager for the Americas. Mr. Scodari previously served as a director of Actelion Pharmaceuticals, Ltd., Endo Health Solutions, Inc. and Covance, Inc. Mr. Scodari has served on various non-profit boards, including the University of the Health Sciences in Philadelphia, the Board of Overseers for the Robert Wood Johnson School of Medicine, and on the Board of Trustees for Gwynedd Mercy College. He has also served on various industry association boards, including the NWDA Associate Member Board, the National Pharmaceutical Council, as Vice Chairman of the Biotechnology Industry Organization (BIO), and Chairman of PA BIO. Mr. Scodari received a B.A. from Youngstown State University.
As the Independent Chairman of the Board of OptiNose Inc, the total compensation of Joseph Scodari at OptiNose Inc is $142,753. There are 10 executives at OptiNose Inc getting paid more, with Peter Miller having the highest compensation of $2,033,500.
Joseph Scodari is 67, he's been the Independent Chairman of the Board of OptiNose Inc since 2017. There are 1 older and 15 younger executives at OptiNose Inc. The oldest executive at OptiNose Inc is Sandra Helton, 70, who is the Independent Director.
Joseph's mailing address filed with the SEC is C/O OPTINOSE, INC., 1020 STONY HILL ROAD, SUITE 300, YARDLEY, PA, 19067.
Over the last 19 years, insiders at OptiNose Inc have traded over $144,654,703 worth of OptiNose Inc stock and bought 116,688 units worth $814,936 . The most active insiders traders include Sriram Venkataraman, Capital Partners Ii Gp, Llc..., eRajat Rai. On average, OptiNose Inc executives and independent directors trade stock every 26 days with the average trade being worth of $106,645. The most recent stock trade was executed by Anthony J Krick on 17 July 2024, trading 6,845 units of OPTN stock currently worth $7,803.
optinose, inc., established in 2010 and headquartered in yardley, pennsylvania, is a publicly traded, global specialty pharmaceutical company focused on serving the needs of patients cared for by ent and allergy specialists. our team of kind, passionate, innovative people is building a new kind of organization without the encumbrances of a company with legacy systems and beliefs. we are unified by a shared mission: to improve lives. we do this while also creating great value for the healthcare system and great outcomes for our stakeholders. as innovators in every aspect of our work, we pursue faster and less costly product development, explore evolving commercial business models, and actively seek innovative ways to be more effective and efficient in all areas of the business. we operate with an overarching commitment to doing what is right. we are committed to working together as a team that chooses to live every day by core company values that guide our daily behaviors, creating a fo
OptiNose Inc executives and other stock owners filed with the SEC include: